- Home
- SEAT vs EYPT Comparison
SEAT vs EYPT Comparison
Compare SEAT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- EYPT
- Stock Information
- Founded
- SEAT 2001
- EYPT 1987
- Country
- SEAT United States
- EYPT United States
- Employees
- SEAT N/A
- EYPT N/A
- Industry
- SEAT Industrial Machinery/Components
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- SEAT Industrials
- EYPT Industrials
- Exchange
- SEAT Nasdaq
- EYPT Nasdaq
- Market Cap
- SEAT 622.1M
- EYPT 489.4M
- IPO Year
- SEAT N/A
- EYPT 2005
- Fundamental
- Price
- SEAT $4.48
- EYPT $7.69
- Analyst Decision
- SEAT Strong Buy
- EYPT Strong Buy
- Analyst Count
- SEAT 10
- EYPT 8
- Target Price
- SEAT $6.73
- EYPT $25.71
- AVG Volume (30 Days)
- SEAT 1.1M
- EYPT 665.0K
- Earning Date
- SEAT 03-04-2025
- EYPT 03-06-2025
- Dividend Yield
- SEAT N/A
- EYPT N/A
- EPS Growth
- SEAT N/A
- EYPT N/A
- EPS
- SEAT N/A
- EYPT N/A
- Revenue
- SEAT $774,076,000.00
- EYPT $45,713,000.00
- Revenue This Year
- SEAT $10.17
- EYPT N/A
- Revenue Next Year
- SEAT $4.02
- EYPT N/A
- P/E Ratio
- SEAT N/A
- EYPT N/A
- Revenue Growth
- SEAT 13.91
- EYPT 7.50
- 52 Week Low
- SEAT $3.24
- EYPT $6.90
- 52 Week High
- SEAT $6.41
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- SEAT 49.56
- EYPT 41.66
- Support Level
- SEAT $4.13
- EYPT $7.58
- Resistance Level
- SEAT $4.78
- EYPT $8.16
- Average True Range (ATR)
- SEAT 0.26
- EYPT 0.55
- MACD
- SEAT -0.08
- EYPT -0.07
- Stochastic Oscillator
- SEAT 26.67
- EYPT 3.06
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.